To analyze the effects of the mutations in the b3-adrenoceptor (b3-AR) gene and/or uncoupling protein3 (UCP3) gene promoter on body fat distribution and glycemic control after mild weight reduction in overweight-obese subjects with coronary artery disease (CAD) or metabolic syndrome. DESIGN: Clinical intervention study of the À300 kcal/day mild weight reduction program for 12 weeks. SUBJECTS: A total of 224 overweight-obese subjects with CAD or metabolic disorder, subdivided into the following four categories: (1) wild type (TT-CC, n ¼ 73); (2) only UCP3 promoter variant (TT-CT/TT, n ¼ 90); (3) only b3-AR variant (TA/AA-CC, n ¼ 29); (4) both variants (TA/AA-CT/TT, n ¼ 32). MEASUREMENT: Body mass index (BMI), blood pressure, calorie intakes, body fat distribution, serum glucose, insulin, free fatty acids, C-peptide and lipids before and after weight reduction. RESULTS: After 12 weeks, all subjects lost approximately 5% of their initial body weight. Despite similar weight reduction, the highest decreases in abdominal adipose tissue at both L1 and L4 levels were observed in the 'wild-type' group (Po0.001) and the second highest in 'only UPC3 promoter variant' group (Po0.001). On the other hand, both variant-carriers had the smallest reduction only in visceral fat area at the L4 level. All subjects except both variant-carriers showed significant reductions in the fasting levels of glucose and FFA. The response areas of glucose (Po0.01) and insulin (Po0.05) were reduced largest in the 'wild-type' group and second largest in the 'UCP3 promoter variant' group. CONCLUSION: All the four groups showed similar weight reduction after À300 kcal/d for 12 weeks. However, the beneficial effects on body fat distribution and glycemic control were greatest in the 'wild-type' group and smallest in 'both variants' group. In addition, these effects were less beneficial in carriers with b3-AR gene variant than with UCP3 gene promoter variant.
Introduction
Weight reduction is known to be a highly effective treatment for overweight-obese patients with risk factors of metabolic syndrome, the development of type II diabetes mellitus (DM) and coronary artery disease (CAD). [1] [2] [3] [4] [5] However, the effects of weight reduction on body fat mobilization and endocrine function are divers. Obesity has multiple causes, and is determined by the interaction between environmental and genetic factors. 6, 7 Genetic factors have been shown to influence a predisposition to obesity, by being associated with body fat mobilization and energy balance. [8] [9] [10] Especially, gene defects showing no or only minor effect when expressed alone might influence on the phenotype when present in combination. Two such variants are the tryptophan-to-arginine (Trp64Arg) missense mutation in the b3-adrenoceptor (b3-AR) and the À55C-T mutation in the putative promoter region of uncoupling protein3 (UCP3) gene. b3-AR is the principle mediator of catecholamine-stimulated thermogenesis and lipolysis, which mainly occur at both subcutaneous and visceral sites. 9, 11, 12 Trp64Arg variant in this receptor has been reported to be associated with increased body weight, clinical features of metabolic syndrome, 13 which include abdominal obesity, atherogenic dyslipidemia, raised blood pressure and insulin resistance. 3, [14] [15] [16] However, controversy exists regarding the association between the Trp64Arg mutation of the b3-AR gene and visceral obesity. Discrepant results may have been due to random sampling variations, small subject number, age, or degree of obesity. UCP3, the predominant proton transporter, abundant in the mitochondria of skeletal muscle, is involved in the regulation of lipids as metabolic substrates, and may lead to heat production rather than energy storage. 17, 18 Therefore, the decreased function or expression of UCP3 due to a variation in the promoter region of UCP3 (À55C-T) could reduce the thermorgenic capacity, alter energy homeostasis and influence predisposition to obesity. 17, 18 Subjects with the TT genotype in UCP3 gene promoter showed more atherogenic lipid profile and higher plasma levels of free fatty acid (FFA) than subjects with other genotypes. 19, 20 UCP3 production is also regulated by b3-AR or b3-adrenergic agonists, which provide FFAs to UCP3. 21, 22 Although the role of UCP3 may have less importance in metabolic function than that of b3-AR, the simultaneous occurrence of mutations in b3-AR gene and UCP3 gene promoter may have more influence on body fat accumulation and serum lipid profiles than that of b3-AR alone. The purpose of this study is to identify that overweightobese individuals with CAD or metabolic disorder, carrying variants both in the b3-AR gene and in the UCP3 gene promoter, have more difficulty not only in reducing abdominal fat tissue but also in improving glycemic control and serum lipid profile than those carrying neither gene variant or only one gene variant after mild weight reduction, by a low caloric diet for 12 weeks.
Subjects and methods

Subjects
The study subjects were recruited concomitantly from participants in a prospective human genetic study, supported by a Genome Research Development Project on Health and Medicine (project # HMG-00-GN-01-0001), Ministry of Health & Welfare from 2001, and meeting the inclusion criteria among the latest anthropometric and lab data, about a month before the start of the study. They were all overweight-obese people (BMIZ25 kg/m 2 ) with metabolic syndrome or CAD. Factors characteristic of the metabolic syndrome included at least two among abdominal obesity (waist circumference: men4102 cm, women488 cm), elevated trigyceride (Z1.69 mmol/l), low HDL-cholesterol (meno1.03 mmol/l, womeno1.29 mmol/l), high blood pressure (Z130/Z85 mmHg) or elevated fasting glucose (Z6.11 mmol/l). 3 The CAD criteria were the required angiographic evidence with 450% occlusion of one or more major coronary arteries, old myocardial infarction (MI), or angina pectoris, but any possible nonatherogenic occlusions such as osteal stenosis and spasm were excluded. Subjects with orthopedic limitations, weight loss/gain over the previous 6 months or any diagnosis of diabetes mellitus, liver disease, renal disease, thyroid or pituitary disease were excluded. Female participants are all in postmenopausal status (the absence of menstrual period for at least 1 y, a folliclestimulating hormone level greater than 30 U/l and not taking hormone-replacement therapy). Finally, 224 subjects meeting these criteria were selected as study subjects. period, all subjects were treated with calorie-restricted diets (300 kcal/day less than their daily requirements), educated to select the substitute food for equal calorie and nutrient components, and then instructed to self-select their food by a dietitian. For example, the amount of cooked rice of each meal was recommended to change from one portion size to three quarters; if one feels hungry, a portion of raw vegetables with few calories such as cucumbers and radish in a day were allowed additionally eaten and their cooking methods were recommended to change; the fried and the sauted, etc, were replaced to the steamed, the broiled and the parboiled, etc. All participants were studied as outpatients and were given written and verbal instructions by a dietitian on how to complete 3-day (2 weekdays and 1 weekend) dietary records and activities per week throughout the whole study period. On the sheet, the subjects were instructed to record the amount of foods before the ingestion and any remaining after ingestion by weighing the foods. 23 At baseline, the average energy intake of the subjects was about 2250 kcal/day with 58% from carbohydrate, 18% from protein and 23% from fat. During the study period, the energy intake of the subjects decreased to about 1950 kcal/day with 61% from carbohydrate, 19% from protein and 20% from fat. To check the participants' compliance during the whole study period, the dietitian interviewed them on a weekly visit basis. They were interviewed to discern whether they were following the program well, including dietary intakes and weight changes. During the study period, all participants were also encouraged to maintain their usual lifestyle.
Deoxy nucleic acid extraction and genetic analysis Genomic DNA was extracted from 5 ml whole blood using a commercially available DNA isolation kit (WIZARD s Genomic DNA purification kit, Promega Corp.,. Madison, WI, USA), according to the manufacturer's protocol. b3-adrenoceptor gene: Genotyping for the Trp64Arg variant in the b3-AR gene was performed according to the method of Widen et al, 24 by polymerase chain reaction. The DNA fragments were visualized by UV illumination using an Image Analyzer (Alpha Imagert 1220, Alpha Innotech Corp., CA, U.S.A.). Uncoupling protein3 gene promoter: The ABI PRISM SNaPshott ddNTP Primer Extension Kit (PE Biosystems, Foster City, CA, U.S.A.) was used to detect single-nucleotide polymorphisms (SNPs) by interrogating individual loci in amplification products. Samples were electrophoresed on ABI PRISM 3700 DNA Analyzer and data were analyzed with GeneScan Analysis Software version 3.1 (Applied Biosystems, Foster City, CA, U.S.A.).
Anthropometries and blood pressure measurement
The body mass index (BMI) was calculated as the body weight in kg divided by height in m 2 . Circumferences of waist and hip were measured in the standing position after normal expiration and waist-to-hip ratio (WHR) was also computed. Blood pressure was read from the left arm with an automatic blood pressure monitor (TM-2654, Japan), while subjects remained seated after 20 min rest. An average of three measurements was recorded for each subject.
Fat and muscle areas at levels of L1, L4, mid thigh and mid calf using a CT scanner Body fat distribution and muscle areas were measured by computerized tomography (CT) scanning using a General Electric (GE) High Speed Advantage 9800 scanner (Milwaukee, WI, USA). Four cross-sectional images were made for each subject: abdomen at the levels of 1st lumbar (L1) vertebra and 4th lumbar (L4) vertebra, thigh (midway between patella and pubis) and calf (at the most protruding area).
Blood collection and lipid profile
Venous blood specimens were collected in EDTA-treated and plain tubes after a 12-h fast. The tubes were immediately covered with aluminum foil and placed on ice until they arrived at the laboratory room (within 1-3 h), and were stored at À701C until analysis. The fasting serum concentration of total cholesterol and triglyceride (TG) were measured with commercially available kits on an Autoanalyzer Hitachi 7150 (Hitachi Ltd, Tokyo, Japan). The HDL cholesterol fraction was measured after precipitation of LDL and VLDL with dextran sulfate-magnesium. LDL cholesterol was estimated indirectly using the Friedewald formula for subjects with serum triglyceride levels o4.52 mmol/l (400 mg/ml). Serum apolipoprotein AI and B were determined turbidimetrically at 340 nm using a specific antiserum agent (Roche, Switzerland).
Oral glucose tolerance test
All subjects underwent a 75 g glucose solution after a 12-h overnight fast. At 0 and 12 weeks, venous specimens were subsequently collected at, before and 30, 60 and 120 min after loading to determine the serum levels and response areas of glucose and insulin according to genotypes. The glucose criteria, newly developed and modified by the National Diabetes Data Group (NDDG) and the World Health Organization Expert Committee on Diabetes Mellitus, was used to categorize subjects as diabetic: symptoms with a casual plasma glucose 411.1 mmol/l (200 mg/dl) or fasting glucose Z7.0 mmol/l (126 mg/dl), and oral glucose tolerance test (OGTT) with a 2-h postload valueZ11.1 mmol/ l (200 mg/dl). 17 Glucose was measured by a glucose oxidase method using the Beckman Glucose Analyzer (Beckman Instruments, Irvine, CA, USA). Insulin and C-peptide were measured by radioimmunoassay with commercial kits from Immuno Nucleo Corp (Stillwater, MN, USA). FFA was analyzed with an Autoanalyzer Hitachi 7150 (Hitachi Ltd, Tokyo, Japan). Each response of glucose, insulin, C-peptide and FFA was calculated with the area under each response curve.
Statistical analysis
The main goal of statistical analysis was to compare the differences in the responses of biochemical parameters according to the mutations of b3-AR gene and/or UCP3 gene promoter. Subjects were classified into the following four categories: (1) Variables that were skewed were log-transformed and then tested. Effects of the diet on end points were tested using a 
Results
Genotypes
Among 224 study subjects, subjects with wild type were 73 (32.6%), subjects with only-UCP3 variant were 90 (40.2%), subjects with only-b3AR variant were 29 (12.9%) and subjects with both variants were 32 (14.3%).
Clinical characteristics, weight change
The initial value of age, body weight, BMI, waist circumference, WHR, blood pressure and percent body fat were not significantly different among the groups (Table 1) . At 0 week, about 16.5% of 224 subjects turned out newly onset DM, based on oral glucose tolerance test, and all groups showed similar proportion. Also, proportions of females, CAD and current smoking and drinking were similar among the four groups. After the intervention, all the four groups showed similar reductions in body weight and BMI (Po0.001). Waist circumferences were also reduced in all the four groups. When divided by gender, male subjects had significant reduction only in 'wild type' and 'only UCP3 promoter variant' groups, and female ones showed it in all the four groups after 12 weeks. However, there was no significance in the net differences among the groups. Both systolic and diastolic blood pressures were significantly reduced in the 'only UCP3 promoter variant' group; however, there was no significance in net differences among the groups. In energy intake, there were no significant difference in the total energy intake and the proportion from each macronutrient among the four groups at baseline, and the proportions were maintained during the study periods (data was not shown).
Body fat and muscle distribution
The initial values of total, visceral and subcutaneous fat areas at both L1 and L4 levels were not significantly different among the four groups. After 12 weeks, 'wild-type' group showed the highest decreases in total and visceral fat areas at both L1 and L4 levels (Po0.001), and 'only UPC3 promoter variant' group showed the second highest at those levels (Po0.001) (Figure 1 ). On the other hand, subjects with only b3-AR variant showed reduction of total and visceral fat areas only at L4 level and both variant-carriers had the smallest reduction only in visceral fat area at L4 level ( Figure 1 ). Subcutaneous fat areas at both L1 and L4 levels were reduced in 'wild type' and 'only UCP3 promoter variant' groups; however, the net differences were not significant among the four groups (Figure 1) . In calf and mid-thigh, the initial fat and muscle areas among four groups were not significantly different, except that the mid-thigh fat area of both variantcarriers was lower than that of wild-type carriers (Po0.05). Both variant-carriers had significant reduction in the midthigh muscle areas (Po0.05) after 12 weeks and the net difference among the four groups is statistically significant (P ¼ 0.047). These groups also showed a reduction in calf fat areas (Po0.01); however, there was no significance in the net difference among the four groups. 'Only b3-AR variant' group showed a reduction in the mid-thigh fat area after the Figure 1 Visceral and subcutaneous fat areas at L1 and L4 levels according to the genotype of b3-AR and/or UCP3 promoter in overweight-obese people with CAD or metabolic syndrome before and after the low caloric diet. Mean7s.e. *Po0.05, **Po0.01, ***Po0.001, compared with the initial value in each group, # P: comparison of net differences among four groups ( #1 total; #2 visceral; #3 subcutaeous).
Additive effect of mutations in b3-AR and UCP3 on body fat OY Kim et al intervention, and it was statistically significant in the net difference among the four groups (P ¼ 0.049) ( Table 2) .
Oral glucose tolerance test Figure 2 and Table 3 show the changes in glucose metabolism before and after 12 weeks. At the start of the intervention, there were no significant differences in serum fasting levels and response areas of glucose, FFA, insulin and C-peptide among the four groups. After the intervention, all the four groups showed significant similar improvement in fasting insulin level. In fasting levels of glucose and FFA, all the study subjects, except those with both variants, showed significant changes; glucose levels (P ¼ 0.049) were reduced and FFA (P ¼ 0.045) were increased. During OGTT, the 'wildtype' group and 'UCP3 promoter variant' group had significant reduction in response areas of glucose (9%, 7%, P ¼ 0.005) and insulin (26%, 16%, P ¼ 0.049). However, there were no significances in the net differences in FFA and Cpeptide areas among the four groups.
Serum levels of lipids
At the start of the intervention, there were no significant differences in serum lipid profile, and apoA1 and apoB lipoprotein among the four groups (Table 4 ). In the withingroup test, 'wild-type' group showed significant decreases in serum fasting levels of TG (10%), atherogenic index (AI, 6%) Additive effect of mutations in b3-AR and UCP3 on body fat OY Kim et al Additive effect of mutations in b3-AR and UCP3 on body fat OY Kim et al and total-to-HDL cholesterol ratio (5%) after weight reduction (Po0.05). Only-UCP3 variant-carriers had a significant decrease in total cholesterol level (4%, Po0.05) after the intervention. However, there were no significances in the net differences of lipid profiles among the four groups, except for a significant reduction in TG level in the 'wildtype' group (0.049).
Discussion
At the start of the study, all the four genotype groups showed similar levels of body weight, BMI, and body fat and muscle areas. After 12 weeks' caloric restriction, all the groups had similar 5% weight reduction. However, the beneficial effects on body fat reduction were greatest in subjects with wild type and smallest in those with both variants. In addition, these effects were less beneficial in carriers with b3-AR gene variant than with UCP3 gene promoter variant. These results can be explained that the b3-AR is almost exclusively expressed in adipose tissue, especially in the visceral fat site, 11, 12, 25, 26 and that subjects carrying the Trp64Arg variant had impaired b3-AR-induced lipolysis. 27 Therefore, it might result in less reduction in visceral fats of Trp64Arg variantcarriers during weight reduction in this study. In glucose metabolism, the 'wild-type' group showed the largest improvement and 'only UCP3 promoter variant' group did the second largest. It is in agreement with the previous report that Trp64Arg mutation of the b3-AR gene was associated with difficulties in improving glycemic control and insulin concentrations during OGTT. 24 In addition, responses of glucose and insulin are sensitively influenced by body fat distribution, especially abdominal visceral fat mass. 28 Therefore, the patterns of glucose metabolism after the intervention might run parallel with those of body fat distribution. In lipid profile, this study showed that subjects with wild type had a reduction in serum TG level. However, there were no significances in the net difference of other lipid profiles among the four groups. It is somewhat different from the reports that subjects with CT or TT genotype of the UCP3-55C/T polymorphism have a more atherogenic lipid profile and higher plasma levels of FFA than subjects with normal genotypes CC. 19, 20 It may suggest that the role of b3-AR should be more responsible for lipid regulation as well as lipolysis from body fat, especially visceral fat area rather than that of the UCP3 gene promoter. However, the effects on glycemic control and lipid profiles according to genotype cannot be defined in a word, because the improved results in subjects with wild type or only UPC3 variant right after the intervention could be due to a negative energy balance instead of weight reduction itself. After the study, all the study participants were advised to maintain the instructed À300 kcal/day diet for the time being (about 2 months) even after the study, and recommended to take light exercise fitting for each one. Some of the CAD patients (not all participants) could be followed up when they visited the hospital. Their body weights were reduced about 1-2% more, and serum levels of glucose, insulin and lipid profiles were shown as similar to the values measured at the end of the study (at 12 week). It might show that CAD patients had weight stabilization after the weight reduction study and maintained serum levels of glucose, insulin and lipid profile measured at the study period. However, it was investigated only in CAD patients and not in all participants. Therefore, studies for weight-reduction effect by caloric restriction according to genotype should include not only weight reduction itself, but also the weight-maintenance period.
Obviously, this study showed that the beneficial effect of mild weight reduction by a low caloric diet on abdominal fat loss is the greatest in subjects with normal homozygotes of b3-AR gene and UCP3 promoter, and the effects are less beneficial in the case with b3-AR variant than in that with the UCP3 promoter variant. Furthermore, the simultaneous existence of mutations in both genes might be more difficult in improving the body fat distribution. These possible additive effects of the mutation both in the b3-AR gene and in the UCP3 gene promoter in response to weight reduction suggest the necessity for further research not only about the polymorphisms in other candidate genes related to obesity, metabolic syndrome or CAD, but also about the effect of mutations on weight maintenance after weight reduction.
